This trial is evaluating whether Lumason Contrast-Enhanced Ultrasound will improve 2 primary outcomes and 1 secondary outcome in patients with Kidney Transplantation. Measurement will happen over the course of Any Time After Kidney Transplantation.
This trial requires 55 total participants across 2 different treatment groups
This trial involves 2 different treatments. Lumason Contrast-Enhanced Ultrasound is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
A nephrectomy in [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant)ation is mainly indicated if a functional graft cannot be maintained. A histological diagnosis is made when posttransplantation graft dysfunction (such as proteinuria) or glomerulosclerosis is present. A pathological evaluation of all grafts is necessary. Nephrectomies in a previously functioning graft can be indicated as a treatment option when it is a prerequisite for subsequent transplantation. In the case of malignancy, this treatment option is not possible. The posttransplantation management in this case is determined by the indication of malignancy. In summary, nephrectomy should be considered in cases of renal failure or a malignancy in a transplanted kidney.
Although a small number of patients have [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant)s purely for economic motives, the majority may derive substantial gains. A number do so as patients with end stage renal disease, others as transplants for familial cystic kidney disease. In certain countries, kidney transplantation is performed for purely financial motives, for example in Brazil, India and Russia. This is an ethical dilemma as the patients have poor insight to the nature and magnitude of their plight. The question is also complicated because renal units are scarce. We argue that there is a distinction in the treatment of end stage renal disease between people who require dialysis and those who should receive, regardless of the financial benefits.
While the initial excitement is over, there is no cure for transplant rejection. Kidney transplantation is still a life-saving treatment for end-stage renal disease, and the potential benefit to the recipient and patient of kidney transplantation is profound.
Approximately 25,000 US renal transplant recipients are awaiting a kidney transplant each year. On average, 4.5 patients die while waiting for a kidney transplant. Survival is better after kidney transplantation but patients may be at greater risk for future malignancies and heart disease.
There are multiple common treatments and procedures for kidney transplantation. The procedure of choice depends on the location and type of donated kidney, and the recipient’s health. The most common options include corticosteroid therapy, anti-rejection, hemodialysis therapy, plasmapheresis, intravenous immunoglobulin, medications that inhibit tacrolimus (Ciclosporin), interferon alfa-2b, and corticosteroids in those who are on immunosuppressants.
It is the replacement of a malfunctioning or diseased kidney with a healthy kidney of the same or another species. Most common type is a donor-recipient transplantation between members of the same species. Kidney transplantation is a highly effective treatment of end-stage kidney disease and an established treatment for select, chronic indications such as autoimmune kidney diseases, hereditary renal diseases, and other genic renal diseases. It is also a potentially curative treatment option for the most common indications of dialysis, and the number of recipients is rising exponentially, especially in Europe.
Clinical trials are an important route for the introduction of new treatments to those on waiting lists for organs. Despite the high probability of rejection in patients who must endure several years of medication before being transplanted, some patients have lived longer than 5 years on the kidney waiting list. Most clinical trials are conducted in the United States and Canada but the National Transplant Network offers free consultation to patients from the United Kingdom in relation to clinical trials for transplant. At present, the National Transplant Network receives information from many countries and they can assist patients in contacting clinical trials in other countries. Most clinical trials are in the first year after transplantation, but there should be more studies on the late effects of the transplant disease.
The existing information about this topic is limited to a limited number of recent and rigorous publications. It is suggested to perform some rigorous and well-designed RCTs to provide more knowledge about kidney transplantation to optimize its long-term outcomes.
Almost all patients are well within the first year after transplantation when they are followed by generalist nephrology clinics. However, if they do have kidney symptoms, they tend to be long-term problems. This problem seems more relevant in renal replacement treatment than in the medical management of patients with end stage kidney disease.
Lumason CEUS is a highly useful method not only for detecting small renal tumors but also for enhancing tumoral-vessel contrast and delineating vascularity. The application of Lumason CEUS will improve quality of life for patients after renal transplantation, and may alleviate patients' fear and anxiety.
There has been some clinical trial evidence of improved cancer outcomes after CHEUS. However, further work is required to establish a full evidence base. The most advanced clinical trials to date are evaluating CHEUS for renal and non-renal cancers. Future clinical trial design considerations should be based on the existing evidence, considering the limitations of CHEUS and the potential advantages of lumason.
Contrary to clinical opinion, the Lumason Imaging System provides good contrast using a low-molecular-weight contrast agent, and thus it may be used to distinguish solid renal lesions from other cysts.